Core Viewpoint - MicroPort Medical (00853) reported HeartCare Medical (688016.SH) 2025 annual performance forecast, showing total revenue of approximately 1.351 billion yuan, a year-on-year increase of 11.96%, and a net profit attributable to the parent company of approximately 563 million yuan, a year-on-year increase of 12.17% [1] Group 1: Financial Performance - Total revenue for the year is approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - Net profit attributable to the parent company is approximately 563 million yuan, with a year-on-year increase of 12.17% [1] - Basic earnings per share stand at 4.65 yuan [1] Group 2: Market Strategy and Sales - The company has strengthened its domestic leading position through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of total revenue [1] - The company is actively promoting its products in Europe, Latin America, and Asia-Pacific, with sales coverage extending to 49 countries and regions [1] Group 3: Product Development and Approvals - Multiple innovative products have been approved for launch in China, including the Cratos branched aortic stent graft system and other medical kits [2] - A total of 23 products have received NMPA registration, and 11 products have been registered in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products entering various stages of clinical trials and regulatory submissions [3]